<DOC>
	<DOCNO>NCT00532493</DOCNO>
	<brief_summary>Background : Posttraumatic stress disorder ( PTSD ) debilitate disable mental disorder afflicts least 25 % Veterans suffer life-threatening war zone trauma . Trauma-related nightmare sleep disturbance among treatment-resistant PTSD symptom Veterans . Increased responsiveness central nervous system ( CNS ) norepinephrine ( NE ) contribute pathophysiology overall PTSD treatment-resistant nighttime symptom . Placebo-controlled pilot study demonstrate generically available CNS-active alpha-1 adrenoreceptor antagonist prazosin substantially reduce PTSD trauma nightmare sleep disturbance improves global clinical status ( sense well ability function ) Veterans . Objective : The primary objective demonstrate large multi-site placebo-controlled trial Veterans war zone trauma-induced PTSD prazosin efficacious PTSD trauma nightmare , sleep disturbance , global clinical status . A secondary objective demonstrate prazosin effectiveness outcome measure clinically meaningful long-term ( 26 week ) maintenance treatment PTSD . The investigator also address prazosin efficacy long-term effectiveness improve total PTSD symptom , comorbid depression , quality life , physical functioning . Methods : This 26 week randomize double-blind placebo-controlled study design demonstrate short term efficacy long term effectiveness prazosin PTSD . The research design encompass shorter-term , tightly control efficacy component longer-term , .real world . effectiveness component . Three hundred twenty-six Veterans war zone -related PTSD persistent trauma nightmare randomize 1:1 prazosin placebo . Study drug increase use flexible dose titration schedule base clinical response adverse effect optimum maintenance dose ( 1-20 mg/day ) . During first 10 week study , participant randomize prazosin placebo . Previous psychotropic medication and/or psychotherapy maintain constant . Short term efficacy determine first 10 week . During remain 16 week 26 week trial , subject continue receive stable-dose double-blind prazosin placebo , option receive additional psychotropic medication and/or psychotherapeutic intervention , need , per judgment study Clinician Prescriber . It hypothesize prazosin remain clinically effective placebo end 26-week trial , demonstrate prazosin add benefit over-and-above treatment naturalistically administer provider .real world . clinical setting . Prazosin judge efficacious 10 week superior placebo three primary outcome measure assess trauma nightmare , sleep disturbance , global clinical status : Recurrent Distressing Dreams item Clinician Administered PTSD Scale ( CAPS ) , Pittsburgh Sleep Quality Index ( PSQI ) , Clinical Global Impression Change ( CGIC ) . Secondary outcome measure assess prazosin effect total PTSD symptom , depression , physical functioning , quality life . Adverse effect cardiovascular measure , include supine stand blood pressure ( BP ) heart rate ( HR ) assess .</brief_summary>
	<brief_title>Cooperative Studies Program # 563 - Prazosin Combat Trauma PTSD</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<criteria>Age &gt; 18 year . Exposure one lifethreatening war zone trauma event per Combat Exposure Scale [ 78 ] document Department Defense ( DD ) Form 214 , Combat Action Ribbon ( Marines ) , Combat Infantry Badge ( Army ) , clear evidence war zone trauma exposure . Eligible VA health care . Diagnostic Statistical Manual Mental Disorders ( DSM ) IV diagnosis PTSD derive CAPS . CAPS total score &gt; 50 . CAPS Recurrent Distressing Dreams item score &gt; 5 ( maximum score 8 ) . Capable give informed consent . Stable dose nonexclusionary ( see ) medication least 4 week prior randomization . Psychotherapeutic treatment stable least 4 week prior randomization . Good general medical health ( see Medical Exclusion Criteria ) . Female participant must agree use reliable form birth control study . Medical : Acute unstable chronic medical illness , include unstable angina , recent myocardial infarction ( within 6 month ) , congestive heart failure , preexist hypotension ( systolic &lt; 110 ) orthostatic hypotension ( systolic drop &gt; 20 millimeter mercury two minute stand drop accompany dizziness ) ; chronic renal hepatic failure , pancreatitis , Meniere 's disease , benign positional vertigo ; narcolepsy . Untreated sleep apnea , diagnose sleep study , exclusionary . Treated sleep apnea ( e.g. , Continuous Positive Airway Pressure , surgery ) exclusionary . Allergy previous adverse reaction prazosin alpha1 antagonist . Wounds require surgery , embed shrapnel , recent surgical amputation comprise exclusion individual otherwise medically eligible . Women childbearing potential positive pregnancy test refusal use effective birth control method , breastfeed exclude . Psychiatric/Behavioral : Meets DSMIV criterion current schizophrenia , schizoaffective disorder , psychotic disorder otherwise specify ( NOS ) , delirium , DSMIV cognitive disorder . Exclusion psychotic disorder confuse combat traumainduced reexperiencing symptom ( transient dissociative state flashback ) , exclusionary . Substance dependence disorder within 3 month current substance dependence ( stable methadone maintenance exclusionary ) . Current cocaine stimulant abuse . Severe psychiatric instability severe situational life crisis , include evidence actively suicidal homicidal , behavior pose immediate danger patient others . Nonsuicidal depression comorbid PTSD exclusionary ( see ) . Medications/Therapies : Current use prazosin alpha1 antagonist . Previous adequate trial prazosin PTSD . Subjects trazodone undergo 2week washout period baseline assessment . ( Combining prazosin trazodone may increase risk priapism ) . Sildenafil ( Viagra ) , tadalafil ( Cialis ) , vardenafil ( Levitra ) permit study dose titration period increase risk hypotension combination alpha1 blocker . Following achieve stable dose study drug , sildenafil , tadalafil , vardenafil permit 1/2 usual start dose . Stimulants alternative medication stimulant property ( e.g. , ephedra ) . Recent exposure therapy and/or Eye Movement Desensitization Reprogramming ( EMDR ) . These therapy must complete &gt; 4 week randomization . Other psychotropic medication and/or maintenance psychotherapy stable dose least 4 week exclusionary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Combat Trauma</keyword>
	<keyword>Post traumatic stress disorder</keyword>
	<keyword>PTSD</keyword>
	<keyword>Sleep Disturbance</keyword>
	<keyword>Trauma-Related Nightmares</keyword>
</DOC>